HongKong:2142

Harbour BioMed Reports Full Year 2023 Financial Results

Retrieved on: 
Donnerstag, März 28, 2024
GMG, Patient, Stock exchange, Quality of life, Protein engineering, Bank statement, Investment, Therapy, Research, HBM, Biotechnology, Partnership, ITM, Motherboard, Trial of the century, Neonatal Fc receptor, Safety, PD-L1, ADC, Hepatocellular carcinoma, Boston Children's Hospital, U.S. FDA, Longevity, MSLN, Harbor, Hospital, NK, Engineering, NMPA, AstraZeneca, Biology, Ecosystem, Idea, Pharmaceutical industry

We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

Key Points: 
  • We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
  • Harbour BioMed recorded the profit of US$22.8 million for the year ended 31 December 2023.
  • This is the first time that the Company has recorded a net profit on its annual financial statements.
  • Looking to the future, Harbour BioMed will keep driving business growth and accomplishing its mission through two key pillars, Harbour Therapeutics and Nona Biosciences.

Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development

Retrieved on: 
Dienstag, Februar 27, 2024
Complex conjugate, Knowledge, Cancer, ITM, Patient, Spacecraft, IND, Doctor of Philosophy, Harbor, MD, HBM, ADC, Pharmaceutical industry

The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.

Key Points: 
  • The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.
  • Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed, "By leveraging our accumulated knowledge of ADC discovery and utilizing our advanced therapeutic antibody platforms validated by partners worldwide, this collaboration will expedite the development of first-in-class ADCs targeting cancer.
  • Gwanghee Lee, Founder and CEO of Boostimmune, stated, "We are excited to collaborate with Nona Biosciences.
  • Through this collaboration, we are confident in making significant strides in addressing the unmet needs of cancer patients."

Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

Retrieved on: 
Donnerstag, Dezember 14, 2023
Harbor, IND, ADC, Pfizer, Therapy, MSLN, Partnership, Cancer, Ecosystem, ITM, Sales, Pharmaceutical industry

Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge technology innovation to novel therapeutics development.

Key Points: 
  • Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge technology innovation to novel therapeutics development.
  • Nona Biosciences is also eligible to receive tiered royalties on net sales ranging from high single digits to high teens.
  • "We are delighted to collaborate with Pfizer, a company that is committed to developing high-impact medicines for people living with cancer," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences.
  • This partnership with Pfizer further enhances Nona's global network of collaborations through innovative models, thereby amplifying the scientific and commercial value of our technology platforms."

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

Retrieved on: 
Montag, August 28, 2023
Cancer, Therapy, Harbor, Lung cancer, Pharmacokinetics, HKEX, MSLN, Mab, Mesothelioma, ADC, Neoplasm, Ecosystem, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Breast cancer, Pharmaceutical industry

HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.

Key Points: 
  • HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.
  • HBM9033 utilizes a tumor specific cleavable linker with a novel topoisomerase inhibitor for improved stability and activity.
  • The unique design for both mAb and linker-payload together has demonstrated superior potency and safety of HBM9033 in pre-clinical studies.
  • This phase I study is to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9033 in subjects with advanced solid tumors.

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

Retrieved on: 
Dienstag, August 8, 2023
Pharmacy, University, Therapy, Doctor of Philosophy, Harbor, Biotechnology, Brandeis University, Melinta Therapeutics, Dana–Farber Cancer Institute, Harvard Medical School, Science, BioMed Central, ImmunoGen, Growth, Dana, Management, Biochemistry, Biology

Dr. Collinson has over 30 years of experience in the pharmaceutical and biotechnology industries.

Key Points: 
  • Dr. Collinson has over 30 years of experience in the pharmaceutical and biotechnology industries.
  • Dr. Collinson began his career as a scientist at ImmunoGen, Inc..
    "As the Company continues to strengthen its global strategy and advance its pipeline, I am delighted to welcome Dr. Collinson to Harbour BioMed.
  • "Harbour BioMed is a company that has demonstrated a strong commitment to the development of next-generation therapeutics and innovations.
  • Dr. Collinson was a post-doctoral fellow at the Dana Farber Cancer Institute and Harvard Medical School.

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Retrieved on: 
Donnerstag, Juni 29, 2023
Biologics license application, Therapy, Harbor, GMG, Clinical trial, Immunology, MD, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, BioMed Central, Neurology, BLA, III, NMPA, Generic drug, Pharmaceutical industry

This is the first BLA accepted by NMPA since Harbour BioMed's establishment.

Key Points: 
  • This is the first BLA accepted by NMPA since Harbour BioMed's establishment.
  • "Anti-FcRn treatment is at the center of focus in gMG disease area.
  • Batoclimab is the first anti-FcRn treatment completed clinical development with positive results and confirmed efficacious and safe in Chinese gMG population.
  • "We are delighted that batoclimab has become our first BLA successfully accepted by the NMPA demonstrating our strong R&D capability.

Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor

Retrieved on: 
Mittwoch, Juni 7, 2023
HBM, Therapy, CSO, Research, Antibody, EMD, Elstar, Drug discovery, Knowledge, Merck, Growth, IND, Fine chemical, Serono

With over 30 years of global experience in biopharmaceutical research and development, Dr. Arkinstall brings a wealth of knowledge and proven leadership to Nona Biosciences.

Key Points: 
  • With over 30 years of global experience in biopharmaceutical research and development, Dr. Arkinstall brings a wealth of knowledge and proven leadership to Nona Biosciences.
  • He is a respected leader in drug discovery with substantial roles under his belt, including Research Head, Chief Scientific Officer (CSO), and Chief Executive Officer (CEO) positions at various pharmaceutical or biotech companies.
  • "I am excited to be supporting Nona Biosciences at this pivotal time in its growth," Dr. Arkinstall said.
  • Dr. Arkinstall's appointment is effective immediately, and he will play an integral role in guiding Nona's strategic direction, external alliances, and overall scientific operations.

Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center

Retrieved on: 
Freitag, Mai 12, 2023
Motivation, HBM, PIRC, R, Research, IND, Harbor, Doctor of Philosophy, Cancer, Management

CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), announced today it has entered into a strategic collaboration agreement with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on Nona's proprietary Harbour Mice® fully human antibody transgenic mice platform.

Key Points: 
  • CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), announced today it has entered into a strategic collaboration agreement with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on Nona's proprietary Harbour Mice® fully human antibody transgenic mice platform.
  • "We are pleased to enter this strategic collaboration with PharmaEssentia," Jingsong Wang, M.D., PhD, Chairman of Nona Biosciences, said, " PharmaEssentia's therapeutic solutions reflect its motivation for reshaping the treatment path for progressive cancers, and we believe that by leveraging Nona's antibody discovery ability, we can accelerate the R&D process of novel therapies."
  • "We are delighted to partner with Nona Biosciences as we continue to expand our research capabilities and technical expertise at our newly established PIRC," said Lih-Ling Lin PhD, Chief Scientific Officer of PharmaEssentia "We look forward to growing our footprint in the Boston area as we assemble our team of scientists and complete the build-out of our new lab space this year."

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses

Retrieved on: 
Mittwoch, April 19, 2023
Diamond, HBM, ITM, Therapy, Hook effect, Fever, Immunity, Research, RNA, Doctor of Philosophy, Washington University in St. Louis, Molecular biology, Orthornavirae, Pathology, WEEV, Washington University School of Medicine, Rabies, Biology, Knowledge, IND, Virus, Disease, Vaccine, MD

"This collaboration represents an exciting opportunity for Nona Biosciences to leverage its fully human antibody H2L2 transgenic mice, together with the technology and expertise in the development of innovative therapeutics," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences.

Key Points: 
  • "This collaboration represents an exciting opportunity for Nona Biosciences to leverage its fully human antibody H2L2 transgenic mice, together with the technology and expertise in the development of innovative therapeutics," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences.
  • "We believe that our collaboration with Dr. Michael S. Diamond's team will lead to breakthroughs in the field of viral therapeutics and ultimately improve patients' lives."
  • Dr. Michael S. Diamond is a Professor of Medicine, Molecular Microbiology, Pathology & Immunology at Washington University School of Medicine.
  • The Diamond laboratory is renowned for its research on molecular basis of disease of globally emerging RNA viruses and its focus on the interface between pathogenesis and host immunity.

Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

Retrieved on: 
Donnerstag, April 6, 2023
HBM, Therapy, Infection, IND, MD, Research, Patient, Doctor of Philosophy, Pharmaceutical industry

CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ), announced today it has entered into a collaboration agreement with ExeVir Bio.

Key Points: 
  • CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ), announced today it has entered into a collaboration agreement with ExeVir Bio.
  • The collaboration aims to accelerate the development of innovative therapeutics for unmet needs in infectious diseases, harnessing the combined expertise and resources of both companies.
  • Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, " By combining our respective expertise in antibody engineering and the disease area, we are confident that this collaboration will yield groundbreaking discoveries and bring us closer to eradicating the most challenging infectious diseases."
  • Dr. Torsten Mummenbrauer, CEO of ExeVir, added, " The collaboration with Nona Biosciences will be an important support in our ongoing research on bringing new infectious diseases treatments to patients and will deliver additional options to ExeVir's pipeline in infectious diseases.